Interim analysis in relapsed/refractory myeloma after 1–3 lines: teclistamab vs PVd or Kd improved estimated 18-month PFS (69.8% vs 26.9%; HR 0.29) and OS (HR 0.60). Grade 3–4 infections 41.6% vs 29.0%; grade 5 events 6.5% vs 3.5%.
RCTn = 593
Touzeau et al. Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy